Mallinckrodt is “suspending” its plan to spin off its specialty generics business, which includes oxycodone and hydrocodone, into a separate company amid market nervousness about the proposed standalone firm’s exposure to potentially big opioid lawsuit payouts.
The company, which is run out of Hazelwood, Missouri and was the largest manufacturer of oxycodone and hydrocodone pain pills when the US opioid crisis was escalating between 2006 and 2012, had said earlier the spin-off could help
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?